Platelets in Cancer: Multifaceted Roles Beyond Hemostasis to Early Detection
Preprint
- 14 March 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Tumor-educated platelets (TEPs) are emerging as powerful minimally invasive liquid bi-opsy modalities for cancer diagnosis and prognosis. Through crosstalk with tumor cells, platelets sequester tumor-derived molecules and exhibit altered RNA splicing, protein content, and activation status, all of which reflect tumor biology. Numerous studies have reported that TEP-based assays can distinguish cancer patients from controls, with sensi-tivities and specificities often exceeding 80%. Furthermore, platelet RNA signatures can identify cancer types and stages, and elevated platelet counts (thrombocytosis) and spe-cific platelet RNA/protein biomarkers are correlated with adverse prognoses in multiple malignancies, including ovarian and lung cancers. Recent large-scale investigations have validated these findings, reinforcing that TEPs are promising diagnostic and prognostic indicators. Despite this potential, some challenges remain. Ensuring sufficient platelet purity, standardizing sample processing, and accounting for non-cancerous conditions that influence platelet profiles remain critical hurdles. Moreover, tumor heterogeneity and dynamic platelet “education” can complicate assay interpretation. Ongoing efforts are focused on refining biomarker panels, improving computational models for classification, and integrating TEP data with other liquid biopsy analytes (e.g., circulating tumor DNA) for enhanced accuracy. Overall, TEP-based liquid biopsy could transform clinical deci-sion-making by enabling the earlier detection of malignancies and more precise prognos-tic assessments. With further validation in large prospective trials, TEP assays may soon provide a routine and cost-effective approach for guiding individualized cancer care.Keywords
All Related Versions
This publication has 101 references indexed in Scilit:
- Improving platelet‐RNA‐based diagnostics: a comparative analysis of machine learning models for cancer detection and multiclass classificationMolecular Oncology, 2024
- The use of platelets as a clinical tool in oncology: opportunities and challengesCancer Letters, 2024
- TEP RNA: a new frontier for early diagnosis of NSCLCJournal of Cancer Research and Clinical Oncology, 2024
- Mean platelet volume as a potential biomarker for survival outcomes in ovarian clear cell carcinomaInternational Journal of Clinical Oncology, 2023
- The role of platelets in the regulation of tumor growth and metastasis: the mechanisms and targeted therapyMedcomm, 2023
- A New Approach to Simplifying and Harmonizing Cancer Clinical Trials—Standardizing Eligibility CriteriaJAMA Oncology, 2022
- Incidence of Cancer Among Adults With Thrombocytosis in Ontario, CanadaJAMA Network Open, 2021
- Circulating platelets as liquid biopsy sources for cancer detectionMolecular Oncology, 2020
- RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer DiagnosticsCancer Cell, 2015
- Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancerBreast Cancer, 2015